Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 5: ONTARGET - background Abb. 6: ONTARGET - from HOPE to ONTARGET Abb. 7: ONTARGET - the HOPE study Aktuelles Bild - Abb. 8: HOPE study results: primary end point Abb. 9: HOPE study results: secondary end point Abb. 10: ONTARGET - Rationale Abb. 11: ONTARGET - rationale Zum letzten Bild
Abbildung 8: HOPE study results: primary end point
In the HOPE population, treatment with ramipril significantly reduced the risk of the combined cardiovascular endpoint (cardiovascular mortality, myocardial infarction and stroke) by 22% (651 patients in the ramipril group vs 826 patients in the placebo group [p<0.001]). [7] Cardiovascular mortality alone was reduced by 26% in the ramipril group compared with the placebo-treated patients (282 patient deaths in the ramipril group and 377 patient deaths in the placebo group [p<0.001]). Similarly, the percentage of patients experiencing myocardial infarction was reduced by 20% by ramipril treatment (459 patients in the ramipril group compared with 570 patients in the placebo group [p<0.001]). Ramipril also reduced the incidence of stroke by 32% (156 patients in the ramipril group compared with 226 patients in the placebo group [p<0.001]). 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
HOPE study results: primary end point
Vorheriges Bild Nächstes Bild   


Abbildung 8: HOPE study results: primary end point
In the HOPE population, treatment with ramipril significantly reduced the risk of the combined cardiovascular endpoint (cardiovascular mortality, myocardial infarction and stroke) by 22% (651 patients in the ramipril group vs 826 patients in the placebo group [p<0.001]). [7] Cardiovascular mortality alone was reduced by 26% in the ramipril group compared with the placebo-treated patients (282 patient deaths in the ramipril group and 377 patient deaths in the placebo group [p<0.001]). Similarly, the percentage of patients experiencing myocardial infarction was reduced by 20% by ramipril treatment (459 patients in the ramipril group compared with 570 patients in the placebo group [p<0.001]). Ramipril also reduced the incidence of stroke by 32% (156 patients in the ramipril group compared with 226 patients in the placebo group [p<0.001]). 7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung